Literature DB >> 26183503

Relationship between infectious gastroenteritis and irritable bowel syndrome.

Motoyori Kanazawa1, Shin Fukudo.   

Abstract

A newly recognized causative factor in a subset of patients with irritable bowel syndrome (IBS) is called post-infectious IBS (PI-IBS). IBS symptoms frequently develop after an acute episode of infectious gastroenteritis. Several studies have been made in our understanding of the concept of PI-IBS. Recent studies suggest that transient or chronic gastrointestinal inflammation may play a role in IBS pathogenesis. PI-IBS can be regarded as a natural experiment model in which an insult in the form of an infective disease impacts on subjects with underlying genetic and psychosocial predispositions who then develop IBS. IBS is likely to be a complex trait wherein variability in clinical presentation is partially explained by heterogeneity in underlying genetic and environmental risk factors for PI-IBS. Further studies on PI-IBS are needed to understand the pathophysiology of functional gastrointestinal disorders and to develop new promising management for such patients.

Entities:  

Mesh:

Year:  2013        PMID: 26183503     DOI: 10.1007/s12328-013-0444-4

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  34 in total

Review 1.  AGA technical review on irritable bowel syndrome.

Authors:  Douglas A Drossman; Michael Camilleri; Emeran A Mayer; William E Whitehead
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

2.  Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis.

Authors:  Alexandra-Chloé Villani; Mathieu Lemire; Marroon Thabane; Alexandre Belisle; Geneviève Geneau; Amit X Garg; William F Clark; Paul Moayyedi; Stephen M Collins; Denis Franchimont; John K Marshall
Journal:  Gastroenterology       Date:  2010-01-04       Impact factor: 22.682

3.  Influence of loperamide on lactose handling and oral-caecal transit time.

Authors:  A Szilagyi; R Salomon; E Seidman
Journal:  Aliment Pharmacol Ther       Date:  1996-10       Impact factor: 8.171

4.  A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.

Authors:  Emma P Halmos; Victoria A Power; Susan J Shepherd; Peter R Gibson; Jane G Muir
Journal:  Gastroenterology       Date:  2013-09-25       Impact factor: 22.682

5.  Postinfectious irritable bowel syndrome--a meta-analysis.

Authors:  Heather A Halvorson; Carey D Schlett; Mark S Riddle
Journal:  Am J Gastroenterol       Date:  2006-08       Impact factor: 10.864

6.  Role for protease activity in visceral pain in irritable bowel syndrome.

Authors:  Nicolas Cenac; Christopher N Andrews; Marinella Holzhausen; Kevin Chapman; Graeme Cottrell; Patricia Andrade-Gordon; Martin Steinhoff; Giovanni Barbara; Paul Beck; Nigel W Bunnett; Keith A Sharkey; Jose Geraldo P Ferraz; Eldon Shaffer; Nathalie Vergnolle
Journal:  J Clin Invest       Date:  2007-02-15       Impact factor: 14.808

7.  Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome.

Authors:  R C Spiller; D Jenkins; J P Thornley; J M Hebden; T Wright; M Skinner; K R Neal
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

8.  Prognosis in post-infective irritable bowel syndrome: a six year follow up study.

Authors:  K R Neal; L Barker; R C Spiller
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

9.  The clinical course of postinfectious irritable bowel syndrome: a five-year follow-up study.

Authors:  In Su Jung; Hee Sun Kim; Hyojin Park; Sang In Lee
Journal:  J Clin Gastroenterol       Date:  2009-07       Impact factor: 3.062

10.  The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors.

Authors:  Kwang Jae Lee; Yeong Bae Kim; Jang Hee Kim; Hoek Chun Kwon; Dong Kyu Kim; Sung Won Cho
Journal:  J Gastroenterol Hepatol       Date:  2008-11       Impact factor: 4.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.